Guangmin Li

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

Tumor Xenografts, Mouse Xenograft Models, Active Dose +18

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger et al. · Cancer Research · 2008 · 1.6K citations

Drug Targeting, Breast Oncology, Disulfide Linkers +12

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

Teemu T. Junttila, Guangmin Li, Kathryn L. Parsons et al. · Breast Cancer Research and Treatment · 2010 · 523 citations

Breast Oncology, Oncology, Medicine +8

Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Jagath R. Junutula, Kelly M. Flagella, Richard Graham et al. · Clinical Cancer Research · 2010 · 289 citations

Hierarchical electrodes of NiCo₂S₄ nanosheets-anchored sulfur-doped Co₃O₄ nanoneedles with advanced performance for battery-supercapacitor hybrid devices

Yu Ouyang, Haitao Ye, Xifeng Xia et al. · Journal of Materials Chemistry A · 2019 · 208 citations

Engineering, Chemistry, Chemical Engineering +18